1	Title	
2		Prevention of cyclical resurgences of COVID-19-like pandemics in the long term:
3		What are the trade-offs?
4		
5		
6	Autho	Drs
7		Ichiro Nakamoto <sup>1*</sup>
8		
9		
10	Affilia	ations
11		<sup>1</sup> School of Internet Economics and Business,
12		Fujian University of Technology, Fuzhou, Fujian Province, China.
13		*Corresponding author Email: ichiro2019@163.com.
14		
15		
16		
17		
18		
20		
20		
22		
23		
24		
25		
26		
27		
28		
29		
30 31		
32		
33		
34		
35		
36		
37		
38		
39		
40 41		
41 47		
⊐∠ 43		
44		
45		
46		

#### 47

#### 48 Abstract

49 Vaccines have facilitated the substantial reduction and containment of COVID-19 transmission in many countries by early 2023. However, the long-term interconnection between vaccines, traits 50 of the pathogen, vaccination strategies, and cases averted/trade-offs of health outcomes is not 51 well understood. Utilizing a compartment-calibrated model, I estimated the aversion/trade-offs 52 effect on six major disease burdens (i.e., total/symptomatic/asymptomatic/hospitalized/ICU/death 53 cases averted) over time conditional on a variety level of scenarios. The findings implied that 54 low-risk immunity profiles of booster doses increased the peak cases averted versus medium- and 55 high-risk counterparts. The effect was most salient for the former paired with enhancing the 56 rollout rate of doses, followed by the medium- and then high-risk scenarios. Positive and 57 temporarily durable aversion effects for the low-risk, in contrast, negative trade-offs and 58 59 decreasing aversion effects for the suboptimal scenarios were observed. While there are heterogeneities in vaccines, public strategies, social efforts, and other considerations, this work 60 can provide an evidence-based rationale for the long-term trade-off analysis of vaccination. 61

#### 62 63

#### 64 Introduction

As of April 2023, a total of over 13 billion doses of COVID-19 vaccines have been administered 65 globally (1-4), which has facilitated the mitigation and containment of SARS-COV-2 66 transmission by this time. Different countries enacted varied campaigns of vaccination in 67 68 compliance with the objectives of health policies to balance the trade-offs between the health output of the populations and economic activities (2,3). Retrospectively, vaccines, transmission 69 traits of the pathogen, and vaccination strategies had a combined impact on the risks of infections 70 and subsequent health outcomes (5-10). The data by WHO indicated that there were more than 71 100 vaccine candidates in clinical usage worldwide by 2023 (1-4). It was of difficulty to exactly 72 73 capture each of the traits of alternative vaccines in model analyses (11-15). There were heterogeneities and uncertainties regarding the landscape of vaccination, immunity-strength and 74 75 immunity-waning profiles of doses, and the social effort (1-5, 16-20). Is there a long-term difference in curbing infections and other disease burdens by enacting the booster vaccination 76 versus a primary strategy conditional on the traits of vaccines? How the effect is impacted by the 77 78 vaccination strategy such as the rollout rate of doses? Furthermore, how to evaluate the potential trade-offs should the immunity profiles of vaccines present heterogeneities? What lessons can be 79 learned from the COVID-19 pandemic to assess the next risk of cyclical resurgence of a novel 80 infectious disease? Should early booster doses for a novel pandemic unveil suboptimal or multi-81 staged efficacy, where is the potential threshold of trade-offs? Here, I utilized a compartment-82 calibrated model to mostly capture the risks of infections and reinfections, vaccine inefficacy, 83 immunity strength/waning of vaccines, rate of rollout, and other confounding factors to project 84 85 the cases averted and trade-offs in the risk appraisal of cyclical resurgences of a COVID-19-like pandemic for stratified health metrics 86 six (i.e., total/symptomatic/asymptomatic/hospitalized/ICU/death cases averted) over a timescale of up to 87 88 5 years.

#### 89

## 90 Methods

Concisely, the transmission of COVID-19-like infectious diseases was divided into multiple compartments, of which primary infections (i.e., initial infections in full susceptibility), reinfections due to waning immunity after recovery (i.e., secondary infections), infections due to inefficacy or multi-staged traits of vaccines after booster vaccination (the rate of which was defined as VI hereafter), immunity waning to susceptibility after booster vaccination (likewise,

96 the rate of which was defined as VS), infections due to immunity waning after booster 97 vaccination (the rate of which was defined as SI), recovery from infections, immunity waning to 98 susceptibility after recovery, rates of vaccination, and vaccination were the major appraised 99 factors in this study (fig. S1, 20-28). The metrics VI, SI, and VS reflected the immunity-strength 100 and immunity-waning profile of booster doses. Theoretically, the greater values of the measures, 101 the lower efficacy of the vaccines (20, 29-33).

102

103 The findings in (7) summarized the breakdown of primary infections, including cases requiring hospitalization, hospitalized cases requiring intensive critical care service (ICU hereafter), and 104 death cases for different age groups. Another survey targeting reinfections showed the statistics of 105 death, hospitalizations, and unclear/asymptomatic infections (8). The total cases in this study were 106 comprised of four sections including primary infections, secondary infections, infections due to 107 the inefficacy of vaccines after vaccination, and infections due to immunity waning of vaccines 108 109 after vaccination. On the other hand, the total cases averted reflected the difference in the number of infections between a primary and a booster strategy, the gap for which could be attributable to 110 multiple factors including the immunity profiles of vaccines, landscape of vaccination, traits of 111 the pathogen, and rate of rollout. To capture the stratified effect of disease burdens in detail, the 112 model divided the initial total cases averted into five stratified health metrics including 113 symptomatic, asymptomatic, hospitalized, ICU, and death cases averted, and the statistics of these 114 115 measures were calculated respectively based on the statistics data in (7) and (8). Additionally, the model assumed: (a) the population was homogenous and identical population size of each age 116 group; (b) individuals with at least one dose vaccinated were infected with no symptoms (i.e., 117 asymptomatic) due to partial immunity protection of vaccines; (c) the relative infectiousness of 118 other types of infections was identical to the primary infections; (d) the primary vaccination was 119 initiated at week 44, nearly eleven months after the establishment of the transmission; (e) to 120 reflect seasonal variation in transmission, the model based seasonal reproduction numbers in this 121 work on those used in (5), which calibrated values to yield the basic reproduction number of 2.3; 122 (f) no constraint of population size was present;(g) the primary vaccination consisted of two doses, 123 and the booster vaccination consisted of one dose or above. 124

125

For purpose of clarity and brevity, the main analysis illustrated the aversion/trade-off effect for a 126 setting with a one-billion population size over an observation period of four years (i.e., 127 equivalently 208 weeks assuming one year consists of 52 weeks) by using a discrete measure of 128 SI from 0.1 to 0.9 in 0.1 increments. I also reflected other varying sizes of populations (i.e., 8e7 to 129 1.2e9), diverse lengths of observation time (i.e., 160 to 260 weeks), varying SI measured in a 130 131 continuous scale, and other key parameters in the online interactive dashboard (34). The sensitivity tests on other sizes of populations and intervals of observations were comparable and 132 generalizable. The robustness tests using a series of key parameters implied that the outcomes 133 were consistent for up to 5 years (Supplementary Material and online interactive dashboard). 134

135 136

## 137 **Results**

## 138 Cyclical trajectory changed with vaccine profiles and vaccination strategies

The model implied that, for a basic reproduction number  $R_0 = 2.3$ , the dynamic trajectory of the cyclical pandemic changed with the SI of booster doses over four years. The appraised scenarios could be classified into three categories: high- (Fig. 1, A to C), medium- (Fig. 1, D to F), and lowrisk resurgence respectively (Fig. 1, G to I). The risk of cyclical resurgence of the epidemic decreased with the reduction of SI values (Fig. 1, A to F). The lower-risk scenario had fewer times of reoccurrence and the pandemic was contained at an earlier time versus the other two scenarios. On the other, the peak sizes of subsequent resurgence after week 156 (i.e., nearly 80

weeks after the initiation timing of booster doses) for the lower-risk scenario were smaller in
magnitude versus the higher-risk counterpart as well (Fig. 1, G, H, and I versus D, E, and F versus
A, B, and C).

149

When the immunity strength of vaccines was productive (Fig. 1, I), both primary and booster 150 vaccination contained the pandemic in three years. Distribution of booster doses reduced the peak 151 sizes of the pandemic versus the primary strategy, which was curtailed more in terms of 152 153 magnitude with the increase in the rollout rate of booster doses. A higher-rate rollout contained the pandemic at an earlier time versus a lower-rate rollout. Asymptotically, the difference in the 154 containment timing of the pandemic between the higher-rate and the lower-rate scenario was 68 155 weeks (i.e., week 88 versus week 156). When SI increased to 0.2 and the effectiveness of 156 vaccines reduced (Fig. 1, H), the curtailing effect resulting from booster vaccination decreased. 157 No differentiated aversion effect of peak sizes was observed by enhancing the rollout rate of 158 doses versus the lower-rate scenarios. A similar trend was captured when SI was equal to 0.3 (Fig. 159 160 1, G). In the medium- and high-risk scenarios, booster vaccination reduced the transmission in the short run (i.e., before week 104), however, cyclical resurgences of the pandemic were likely to 161 occur in the long run (Fig. 1, A to F). 162

163

Substantial weekly cases were averted in a short period in the cases where the rollout of booster 164 doses was productive (Fig. 2, I), which facilitated the expeditious mitigation and depletion of the 165 166 transmission. And the higher-rate scenario was expected to attain a greater aversion in magnitude versus the lower-rate counterpart. For instance, 514026 weekly cases were averted for the former 167 168 (i.e., a rate equal to 4 per year) versus 333809 weekly cases averted for the latter (i.e., a rate equal to 0.5 per year) at week 80 (Fig. 2, I). When SI increased, the weekly difference of cases averted 169 between the higher- and lower-rate strategy decreased. From a long-term perspective, the positive 170 effect of aversion resulting from booster doses transformed into a negative effect with the 171 increase of SI values (Figs. 2, A to H). 172

- 173
- 174

medRxiv preprint doi: https://doi.org/10.1101/2023.04.16.23288641; this version posted April 17, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.





Fig. 1. Simulated trajectory of cyclical resurgence. The impact of immunity profiles of 177 vaccines and social efforts on the cyclical occurrences of a COVID-19-like pandemic over four 178 179 years assuming one year is comprised of 52 weeks. SI varies from 0.9 (A) to 0.1 (I) in 0.1 discrete increments. For each SI scenario, the primary strategy consists of two doses, and the higher and 180 lower rollout rate of booster doses is equal to 4 and 0.5 per year, mimicking scenarios of 181 productive and non-productive distribution respectively. Shaded light-color areas delineate the 182 95% confidence intervals of the simulations. Orange color bars represent the spacing between the 183 primary doses, and the dashed orange line describes the initiation timing of booster doses. For 184 clarity, I illustrate the trajectory for an 8-week primary spacing and a 24-week booster spacing. 185

186 187

188

medRxiv preprint doi: https://doi.org/10.1101/2023.04.16.23288641; this version posted April 17, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.





Fig. 2. Simulation of weekly cases averted. Weekly new cases averted for SI ranging from 0.9 191 (A) to 0.1 (I) in 0.1 increments in a four-year timescale assuming one year consists of 52 weeks. 192 For each SI scenario, higher (purple curves and shaded areas) and lower (green curves and shaded 193 areas) rollout rate of booster doses is equal to 4 and 0.5 per year respectively. Shaded light-color 194 areas delineate the 95% confidence intervals of simulations. Orange color bars (weeks 44 and 52) 195 represent the spacing of the primary doses, and dashed orange line (week 76) represents the 196 initiation timing of booster doses. 197

- 198
- 199
- 200
- 201
- 202
- 203
- 204

This section focused on the estimates of the cases averted for the stratified health outcomes 205 206 including total cases, symptomatic cases, asymptomatic cases, hospitalized cases, ICU cases, and death cases averted over four years. Generally, the results could be divided into three groups 207 including high- (Fig. 3, I1 to I6), medium- (Fig. 3, H1 to H6), and low-salient scenarios (Fig. 3, 208 209 A1 to G6) conditional on the magnitude of aversion and the difference between productive and non-productive rollout of doses respectively. 210

211

In the high-salient cases (Fig. 3, I1 to I6), each of the disease burdens yielded a non-decreasing 212 and salient aversion in terms of magnitude accrued over time. For instance, the curves of the total 213 cases averted observed the peak date (i.e., the timing of yielding the maximum cases averted) of 214 week 145 for a higher- versus earlier week 128 for a lower-rate vaccination. The former was 215 expected to yield a cumulative saturation of 8.190465e+08 (95% CI: 434346410, 1203746552, 216

hereafter CI) cases averted, and the latter 3.282357e+08 (CI: 194672962, 461798377) cases 217 averted at the peak points respectively (Fig. 3, I1, and Supplementary data file S1). The aversion 218 rate was roughly 81.9% for the higher- and 32.8% for the lower-rate rollout respectively divided 219 by an assumed one-billion population size taking into account the risks of reinfections, the 220 difference in vaccination strategies, the traits of disease transmission, and the traits of vaccines. 221 222 For each stratified metric under the same level of SI, the cases averted remained at the commensurate level relative to the peak sizes at the end of appraisal time, implying a robust and 223 224 consistent aversion effect when SI values were lower. In a salient-effect scenario, a highercapacity rollout could capture an effect of more than double-fold versus the lower-capacity 225 counterpart (Fig. 3, I1 to I6, and Supplementary data file S1). When SI transferred to the medium-226 salient scenario in which SI=0.2 (Fig. 3, H1), the cases averted for the total cases dropped versus 227 the high-salient scenario in which SI=0.1(Fig. 3, I1). Asymptotically, the peak date shifted to 228 229 week 137 for the higher- and week 133 for the lower-rate scenario, the peak size of which was 230 285826987(CI: 167652930, 404001045) for the former and 223255075 (CI: 134128570, 312381581) for the latter respectively (Fig. 3, H1, and Supplementary data file S1). This implied 231 a nearly 28.6% and 22.3% aversion rate under the same size of the population previously. In the 232 medium- and high-salient cases, the size averted for the total cases decreased over time after the 233 peak-date point (Fig. 3, A1, B1, C1, D1, E1, F1, G1, and Supplementary data file S1). In a similar 234 vein, at SI=0.3, the peak date observed was at the commensurable point of time for the higher-235 versus for the lower-rate scenario, and 247459708 (CI: 146289736, 348629681) versus 236 2.378337e+08 (CI: 140641248, 335026083) in magnitude respectively (Fig. 3, G1, and 237 Supplementary data file S1). It could be seen that with the increase of SI, the gap of cases averted 238 between productive and non-productive rollout lessened or reversed at certain points (Fig. 3, A1, 239 B1, C1, D1, E1, F1, and Supplementary data file S1), suggesting the limited effect of rollout 240 capacity enhancing and the complexity of the transmission when vaccines were ineffective. The 241 242 greater values of SI, the faster reduction in the cases averted over time after the peak points, indicating the earlier terminating of the positive effect (Fig. A1, B1, C1, D1, E1, F1, G1, H1, and 243 Supplementary data file S1). 244

245

Consistently, the trending observed for total cases averted applied to the other five stratified 246 disease burdens including symptomatic, asymptomatic, hospitalized, ICU, and death cases averted 247 when SI=0.1 (Fig. 3, A2 to I6). For instance, the estimated peak date for maximum symptomatic 248 249 cases averted was week 146 for the higher- versus week 115 for the lower-rate scenario, and the peak size averted was 3.373556e+08(CI: 175563367, 499147914) versus 9.617363e+07(CI: 250 62891532, 129455724) (Fig. 3, I2, and Supplementary data file S1), implying a 33.74% and 251 9.62% aversion rate respectively. In a comparable analysis, asymptomatic cases averted observed 252 253 the peak date of week 146 versus week 128, and the peak size averted of 4.189621e+08 (CI: 224273867, 613650426) versus 2.154589e+08 (CI: 127649753, 303268108) respectively (Fig. 3, 254 I3, and Supplementary data file S1), indicating a 41.9% and 21.55% aversion rate. As for 255 hospitalization cases averted, the data yielded the peak date of week 146 versus week 128, and the 256 peak size averted of 4.795871e+07 (CI: 25191367, 70726047) versus 1.562443e+07 (CI: 9089754, 257 22159110) (Fig. 3, I4, and Supplementary data file S1), the aversion rates of which were 5.00% 258 259 and 1.56% respectively. The peak date for ICU cases averted was estimated at week 146 versus week 128, and the peak size averted captured a magnitude difference of 9591741 (CI: 5038273, 260 14145209) versus 3.124887e+06 (CI: 1817950, 4431822) (Fig. 3, I5, and Supplementary data file 261 262 S1). Analogous calculation yielded aversion rates of 1% and 0.3%. Finally, death cases averted estimated the saturation points of week 146 versus 129, and the saturation size averted of 263 2.745773e+07 (CI: 14578065, 40337389) versus 1.249529e+07 (CI: 7122512, 17868064) (Fig. 3, 264 265 I6, and Supplementary data file S1), for which the aversion rates were 2.75% and 1.25%. To sum up, when SI was low, enhancing the rollout rate of booster doses increased the cases averted and 266

the effect of aversion was robust over time after the peak dates for symptomatic, asymptomatic, hospitalized, ICU, and death cases. The peak dates were reached approximately after 61 to 70 weeks of the rollout for the higher-rate scenario and 39 to 52 weeks for the lower-rate scenario, suggesting the complexity of the disease transmission.

271

In the scenarios where the SI value increased to 0.2, the cases averted for each of the stratified 272 disease burdens reduced in magnitude (Fig. 3, H1 to H6). Representatively, symptomatic cases 273 274 averted observed the homogeneous peak date of week 119, whereas the peak size of 77612795 (CI: 49790759, 105434831) for the high- versus 59550066 (CI: 39163409, 79936723) for the 275 low-capacity scenario (Fig. 3, H2, and Supplementary data file S1), which resulted in a 7.76% 276 and 5.96% aversion rate respectively. Likewise, the simulation forecast the peak date of week 140 277 278 versus week 136 for asymptomatic cases averted, and the peak size averted of 192469959 (CI: 112526792, 272413128) versus 1.516442e+08 (CI: 90813414, 212474984) (Fig. 3, H3, and 279 Supplementary data file S1), producing a 19.25% and 15.16% aversion rate. For the 280 281 hospitalization scenario, the projected values were week 144 versus week 131, and 12883256 (CI: 7331233, 18435280) versus 10212040 (CI: 6039796, 14384285) (Fig. 3, H4, and Supplementary 282 data file S1), yielding the aversion rate of 1.29% and 1%. The ICU scenario observed week 132 283 versus week 131, and peak size averted of 2654109 (CI: 1543704, 3764514) versus 2042408 (CI: 284 1207959, 2876857) (Fig. 3 H5, and Supplementary data file S1), from which computing the 285 aversion rate of 0.3% versus 0.2%. Finally, the peak date of week 142 versus week 139 for death 286 287 cases averted, and the peak size averted of 10742189 (CI: 6086897, 15397481) versus 8460058 (CI: 4877025, 12043092) (Fig. 3, H6, and Supplementary data file S1), representing the aversion 288 rate of 1% and 0.8%. The peak dates were reached with a slightly earlier time for the higher-rate 289 290 scenario versus SI=0.1.

291

292

293 When the SI value increased to 0.3 or greater, the cases averted decreased further for each stratified disease burden (Fig. 3, A1 to G6, and Supplementary data file S1). The gap of cases 294 295 averted for each metric reduced or reversed between higher- and lower-capacity scenarios when 296 SI inflated. Taking the scenario SI=0.3 as an illustration, the peak size averted for symptomatic cases curtailed to 61559292 (CI: 38861942, 84256642) versus 58618482 (CI: 37067324, 297 80169641) (Fig. 3, G2, and Supplementary data file S1). The asymptomatic cases averted 298 observed similar trending, the peak size averted downsized to 1.703002e+08 (CI: 100268604, 299 240331865) versus 1.641417e+08 (CI: 96645891, 231591011) (Fig. 3, G3, and Supplementary 300 data file S1). This lowered to 1.106625e+07 (CI: 6444994, 15687515) versus 1.059409e+07 (CI: 301 6169283, 15018895) for hospitalized cases (Fig. 3, G4, and Supplementary data file S1). And the 302 peak ICU cases averted shrank to 2213250 (CI: 1288998, 3137502) versus 2.118818e+06 (CI: 303 1233856, 3003778) (Fig. 3, G5, and Supplementary data file S1). Finally, peak death cases 304 305 averted dropped to 9249231 (CI: 5263545, 13234918) versus 8.902579e+06 (CI: 5064754, 12740403) respectively (Fig. 3, G6, and Supplementary data file S1). The positive role played by 306 enhancing the rollout rate of booster doses reduced with the increase of SI values. Greater values 307 308 of SI also curtailed the magnitude of aversion and terminate the positive aversion effect earlier 309 versus lower values.

310

311



312 313

314 Fig. 3. Simulation stratified cases averted for six major disease burdens. Simulation of the aversion effect for major metrics of health outcomes with SI ranging from 0.9 (A1 to A6) to 0.1 315 (I1 to I6) in 0.1 increments. All scenarios sketch the cumulative cases averted over four years. 316 "Total averted" scenario denotes the total cases averted; "Symp. averted" depicts the symptomatic 317 cases averted; "Asym. averted" represents the asymptomatic cases averted; "Hosp. averted" 318 represents the hospitalization cases averted; "ICU averted" outlines the number averted of 319 320 patients needing intensive care unit; "Death averted" delineates the death cases averted. For each SI scenario, higher (purple curves and shaded areas) and lower (green curves and shaded areas) 321 322 rollout rates of booster doses are equal to 4 and 0.5 per year respectively. Shaded light colors sketch the 95% confidence intervals of the simulations. A more detailed continuous measure of SI, 323 differentiated rollout rates of booster doses, diverse booster spacing, varying length of 324 observation time, and other key parameters are delineated in the online interactive dashboard. 325

- 326
- 327
- 328

329 330

# 7 Trade-offs when immunity profiles of vaccines transformed to suboptimal

I estimated the trade-offs for the stratified cases averted over four years when the immunity 331 profiles of booster doses changed to suboptimal by varying SI and VI from 0 to 1.0 using 50 332 simulations for each measure using the previous population size ceteris paribus (Fig. 4, A to F). 333 334 The main analysis illustrated the outcomes for the higher-rate rollout scenario, and the lower-rate scenario implied a similar effect of trending (Fig. S25, A to F). The parameters used in the 335 336 simulation were outlined in the Supplementary Material (Table S2). Consistently, all the stratified health metrics including total, symptomatic, asymptomatic, hospitalized, ICU, and death cases 337 averted observed positive trade-offs when the values of SI and VI were lower (i.e., the areas 338 where values asymptotically lower than 0.2), and negative trade-offs when suboptimal (i.e., the 339 areas where values asymptotically greater than 0.2). For instance, when VI=0.3 and SI=0.3 ceteris 340 paribus, the estimate asymptotically yielded the negative trade-offs of -5e8 cases for total cases 341 averted (Fig. 4, A), -4e7 cases for symptomatic cases averted (Fig. 4, B), -4e8 cases for 342 asymptomatic cases averted (Fig. 4, C), -2e7 cases for hospitalized cases averted (Fig. 4, D), -5e6 343 cases for ICU cases averted (Fig. 4, E), and -2e7 cases for death cases averted using a population 344 345 size of 1e9 respectively (Fig. 4, F). These values reflected the rates of social cost of 50%, 4%, 40%, 2%, 0.5%, and 2% respectively. The greater values of SI and VI, the larger effect of 346 negative trade-offs. 347

348

349



Fig. 4. Simulation trade-offs of disease burdens varying SI and VI from 0 to 1. Simulation of the cumulative stratified cases averted over four years with SI and VI ranging from 0 to 1.0 using 50 simulations for each metric respectively. The population size is equal to 1e9. Positive numbers on each curve illustrate the positive cases averted for each health outcome, and negative numbers depict the negative trade-off when VI and SI transform to sub-optimal ceteris paribus. The rollout rate of booster doses is 4 per year, representing the productive rollout scenario.

357 358

359 In this section, I performed analysis on the trade-offs for the same stratified health metrics with SI 360 and VS varying from 0 to 1.0 using 50 simulations for each respectively (Fig. 5, A to F). 361 Consistent with previous findings, all measures observed a positive aversion effect when VS and 362 SI were lower. The effect transformed to negative trade-offs when VS and SI were suboptimal 363 ceteris paribus. For instance, when VS=0.3 and SI=0.6, the range of trade-offs was approximately 364 [-1e9,-5e8] for total cases averted (Fig. 5, A), [-6e7,-4e7] for symptomatic cases averted (Fig. 5, 365 B), [-1e9,-5e8] for asymptomatic cases averted (Fig. 5, C), [-4e7, -2e7] for hospitalized cases 366 averted (Fig. 5, D), [-1e7, -5e6] for ICU cases averted (Fig. 5, E), and [-4e7, -2e7] for death cases 367 averted respectively (Fig. 5, F). These reflected the rate ranges of social cost of [50%, 100%], 368 [4%, 6%], [50%, 100%], [2%, 4%], [0.5%, 1%], and [2%, 4%] respectively. The parameters used 369 in the simulation and the outcomes were summarized in the Supplementary Material (Table S3, 370





376

375

**Fig. 5. Simulation trade-offs of disease burdens with varying immunity profiles using VS** and SI. Simulation of the cumulative stratified cases averted over four years with SI and VS ranging from 0 to 1.0 using 50 simulations for each metric respectively. The population size is equal to one billion. Positive numbers on each curve illustrate the positive cases averted for each health burden, and negative numbers depict the negative trade-off when VI and SI are sub-optimal ceteris paribus. The rollout rate of booster doses is 4 per year, representing the productive rollout scenario.

- 384
- 385
- 386
- 387



389

390 Next, I estimated how the values of SI and VI contributed to the positive effect of aversion by concentrating on the interval [0, 0.1] where the immunity profiles of vaccines are productive, for 391 both measures (Fig. 6, A to F). The results implied that lower values of VI and SI reduced the 392 social cost and yielded a greater magnitude of effect versus higher-value counterparts for total, 393 symptomatic, asymptomatic, hospitalized, ICU, and death cases averted. For instance, when 394 395 VI=0.05 and SI=0.05, the cases averted were asymptotically 8e7 for total cases (Fig. 6, A), 1e7 for symptomatic cases (Fig. 6, B), 6e7 for asymptomatic cases (Fig. 6, C), 3e6 for hospitalized 396 397 cases (Fig. 6, D), 6e5 for ICU cases (Fig. 6, E), and 3e6 for death cases respectively (Fig. 6, F). These produce the aversion rate of 8%, 1%, 6%, 0.3%, 0.06%, and 0.3% respectively. 398







Fig. 6. Simulation stratified cases averted for disease burdens with SI and VI between 0 and 0.1. Simulation of the stratified cases averted over four years for the six major health burdens with SI and VI varying from 0 to 0.1 using 50 simulations for each metric respectively. The population size is equal to 1e9. Positive numbers on each curve illustrate the positive aversion effect, and negative numbers depict the negative trade-off for each health outcome when VI and SI are sub-optimal ceteris paribus. The rollout rate of booster doses is 4 per year, representing the productive rollout scenario.

- 411
- 412
- 413 414

415

426 427

The estimates of SI and VS varying from 0 to 0.1 were analyzed in a similar vein (Fig. 7, A to F). 416 For a constant value of SI=0.04 and population size of 1e9, calibration of VS from 0.07 to 0.05 417 418 asymptotically engendered positive cases averted of 2e7 for total cases (Fig. 7, A), 2e6 for symptomatic cases (Fig. 7, B), 2e7 for asymptomatic cases (Fig. 7, C), 1e6 for hospitalized cases 419 (Fig. 7, D), 2e5 for ICU cases (Fig. 7, E), and 1e6 for death cases (Fig. 7, F). In contrast, when 420 421 VS=0.05 and SI=0.05, the cases averted were asymptotically [6e7,8e7] for total cases (Fig. 7, A), [8e6,1e7] for symptomatic cases (Fig. 7, B), [4e7, 6e7] for asymptomatic cases (Fig. 7, C), [2e6, 422 3e6] for hospitalized cases (Fig. 7, D), [4e5, 6e5] for ICU cases (Fig. 7, E), and [2e6, 3e6] for 423 424 death cases respectively (Fig. 7, F). These outcomes reflected the rates of aversion effect of [6%, [0.8, 1%], [4%, 7%], [0.2%, 0.3%], [0.04%, 0.06%], and [0.2%, 0.3%] respectively. 425



428 429

Fig. 7. Simulation stratified cases averted for major disease burdens with SI and VS.
 Simulation of the stratified cases averted over four years for SI and VS varying from 0 to 0.1

using 50 simulations for each metric respectively. The population size is equal to 1e9. Positive
numbers on each curve illustrate the positive aversion effect, and negative numbers depict the
negative trade-off for each health outcome when VS and SI are sub-optimal ceteris paribus. The
rollout rate of booster doses is 4 per year, representing the productive rollout scenario.

- 436
- 437 438

#### 439 Sensitivity tests of cases averted using major parameters

440 **One-way sensitivity analysis** 

I performed a series of sensitivity analyses on the stratified cases averted for all six disease burdens by employing key parameters of the transmission, traits of the pathogen, traits of vaccines, and vaccination strategies. For each of the parameters, changing a specific metric ceteris paribus to project the update of aversion trajectory.

*Rate of waning to susceptibility after vaccination.* Experiments conducted on recovered patients found heterogeneous levels of detectable SARS-CoV-2 neutralizing antibodies, implying a differentiated rate of immunity waning to susceptibility after vaccination (7-16, 25-29). I tested the sensitivity across high-, medium-, and low-risk scenarios for primary doses, and the major findings were robust (figs. S2 to S7).

*Rate of birth and death.* Considering the years of evaluation, the population might change during the period (20, 22-28). I estimated two scenarios corresponding to a slower rate and a faster rate of population change respectively. The outcomes did not change qualitatively (figs. S8 to S9).

454 *Vaccination rate of primary doses.* Studies in (20-26,29-34) suggest that the vaccination rate of 455 doses could impact the trajectory of disease transmission. I tested these scenarios and the 456 outcomes remained qualitatively the same as in the main analysis (figs. S10 to S11).

*Vaccination rate of booster doses.* To test how the change in the vaccination rate of booster doses played roles in the trajectory of aversion effect (35-42), a greater rate and a slower rate were used respectively (fig. S12 to S13). Other rollout rates of booster doses can be found in the online interactive dashboard (34). The robustness test for this parameter also supported the consistency.

*Timing of vaccination of booster doses.* The timing of the vaccination potentially exerted an impact on the transmission and hence the aversion track (20, 43-48). I tested two scenarios by shifting the timing of booster doses to an earlier/delayed point respectively, and the results were qualitatively unchanged (figs. S14 to S15). As expected, delaying the rollout of booster doses yielded a curtailed aversion effect.

*Initial size of infections.* I tested the scenarios with greater and smaller sizes of initial infections
 respectively (20, 49-54), and the outcome remained at the commensurate level (figs. S16 to S17).
 The tests using a different initial ratio of secondary over primary infections also supported this
 robustness (34).

*Size of population.* The model did not place constraints on the population size. The main analysis presented the outcomes corresponding to a setting with one-billion population size (20,35-38). I also tested the scenario where the population size was equal to one-tenth of the onebillion size and the analysis implied a comparable outcome (fig. S18 to S22). For the effects on other sizes of populations, please refer to the online interactive dashboard (34).

476 *Rate of waning to secondary susceptibility after recovery.* Patients either obtained natural 477 and/or vaccination immunity after recovery, which reduced over time and individuals could be

exposed to reinfections at a later time (20, 25-33). I tested the rate of waning to secondary
susceptibility after recovery and the results qualitatively identified the robustness(34).

- 480
- 481
- 482

### 483 Multiway sensitivity analysis

Additionally, I selected seven parameters (susceptibility rate to infection after immunity of dose 484 485 1&2 wanes, rate of waning to susceptibility after dose 1&2 vaccination, rate of infection after dose 1&2 vaccination, rate of waning to secondary susceptibility after recovery) for which the 486 uncertainties were of concerns and tested two combinations of these major parameters (figs. S23 487 to S24). The cases averted were quite robust in these analyses as well (figs. S23 to S24). For more 488 detailed information regarding the length of observation time, continuous measure of SI, sizes of 489 populations, initiation timing of booster vaccination, other key parameters, and how the 490 responsiveness of the results to the parameters, please refer to the online interactive dashboard 491 492 (34).

- 493
- 494
- 495
- 496

#### 497 **Discussion**

The findings suggest that, assuming  $R_0 = 2.3$ , booster vaccines with low-risk immunity profiles 498 could produce a salient effect for major disease burdens including total, symptomatic, 499 500 asymptomatic, hospitalized, ICU, and death cases averted up to 5 years, the magnitude of which is followed by medium- and then high-risk counterparts respectively. Enhancing the rollout rate of 501 booster doses yields a greater and more durable aversion effect over time after the peak points 502 503 versus lower-rate rollout scenarios when SI was low, and the effect was reduced with the increase of SI values. In a setting with a one-billion of population size and SI=0.1, the peak aversion rate 504 of total cases was approximately 81.9% for the higher-rate rollout (i.e., a rate equal to 4 per year) 505 versus 32.8% for the lower-rate rollout (i.e., a rate equal to 0.5 per year), 33.74% versus 9.62% 506 for peak symptomatic cases, 41.9% versus 21.55% for asymptomatic cases, 5.00% versus1.56% 507 for hospitalization cases, 1% versus 0.3% for ICU cases, 2.75% versus 1.25% for death cases 508 respectively. These rates reduced to 28.6% versus 22.3%, 7.76% versus 5.96%, 19.25% versus 509 15.16%, 1.29% versus 1%, 0.3% versus 0.2%, 1% and 0.8% respectively when SI=0.2 and lower 510 when SI values were greater. Enhanced social effort facilitated the rapid mitigation and 511 containment of the pandemic when SI was low, whereas the gap of the aversion effect was 512 reduced when SI increased (20-23, 39-45). The greater values of SI, the faster reduction in the 513 cases averted over time after the peak points and the earlier termination of the positive aversion 514 effect. When immunity profiles of vaccines (e.g., SI, VI, and VS) transformed from productive to 515 516 suboptimal, negative trade-offs were observed for all disease burdens. The findings were consistent with other vaccine modeling studies (20-28,54-55). The greater values of SI, VI, and 517 VS, the larger the negative trade-offs generated. The results suggest that enhanced social effort 518 519 through the rollout improvement of booster doses facilitated the control of disease transmission when the immunity profiles of doses were productive. 520

521

522 Many countries used nearly three years or more to control and/or mitigate the spread of the 523 COVID-19 pandemic, and the diminishing of the transmission reflected substantial collaborations 524 and effort (35,39-45). Here, a compartment-refined model was utilized to determine the cases 525 averted and trade-offs for stratified disease burdens up to 5 years. The outcomes were consistent

over time for total, symptomatic, asymptomatic, hospitalized, ICU, and death cases averted. I 526 have assumed a plain framework for capturing the critical traits of SARS-CoV-2 booster vaccines 527 or other infectious diseases that would partially share similar traits with SARS-CoV-2. Nearly 20 528 529 years passed since the first outbreak of the SARS pandemic in 2003 (1-4,20-24), and it could be difficult to pinpoint the next risk. However, it is expected that when vaccines are available should 530 531 a novel infectious disease emerge, more scientific knowledge about the mechanisms, including the viral load trajectory, the relationship with dynamic infectiousness, and the vaccination 532 533 strategies would accrue over time, allowing refinement of the modeling and projection feasible (20-23,49-53). In practice, the magnitude of the effect can be updated by calibrating the 534 parameters to new settings as more information unfolds. 535

536

This study has several limitations. First, the model assumed an equal and constant infectiousness 537 profile for different types of infections including primary, secondary, and other infections. 538 Scientific knowledge of the information for viruses and subsequent variant sub-lineages is 539 540 incomplete and more observations are necessary, although some studies have made progress in this direction (26-31, 46-51). If the infectiousness profiles of different infections change over 541 time, then the findings need to update when more accurate and dynamic data are available (20-542 25). Second, the model assumed a constant immunity-waning rate, infection/reinfection rate, and 543 other rates, however, these conditions could modify in practice conditional on the transmission 544 complexity of the pathogen and the traits of vaccines (20,32-39). As more detailed measures are 545 546 available, the model can be recalibrated to reflect the updated information. Third, the model neither captured geographical/age/contact nor the primary-spacing differences, however, these 547 factors potentially exerted a non-negligible impact on the stratified disease burdens (20-24, 31-548 549 35). As the population makeup, geographic traits, and social contacts could be very different across settings, and similarly the primary-dose spacing for vaccines. Potentially these were the 550 key to determining region-, age-, contact-, and spacing-based estimates of cases averted and 551 552 trade-offs. Fourth, I used the rates of various disease burdens published in (7) and (8), and the seasonal reproduction number published in (20) to project the potential impact, but these statistics 553 might vary vastly over time and/or over locations. In these cases, models need to be refined and 554 555 calibrated to reflect the temporal and geographic context. And the generalization of the results needed to be exercised with caution. Fifth, I assumed a two-dose primary strategy, which could 556 be different for the differentiated practices in countries. Further, I used three critical traits of 557 558 vaccines to estimate the stratified effect, whereas other important measures connected with the stratified disease burdens potentially present. For instance, occupation and vaccination hesitancy 559 was potentially linked to an increased risk of asymptomatic and symptomatic infections in certain 560 settings (12-18, 33-37). Furthermore, several studies (38-46) identified that, as a result of 561 562 healthcare in-equilibrium, individuals from racial and ethnic minority groups were exposed to increased risk versus their counterparts in certain countries. These are critical considerations in 563 further directions of studies to identify more detailed effects for the stratified disease burdens. 564

565

Finally, I have explored the simplest framework, which can only provide a general implication of 566 the aversion potential for the stratified measures of health outcomes under different scenarios 567 should a COVID-19-like pandemic occur. Including more complicated evolutionary components 568 (20, 41-48) in the model is an important direction for future work. Heterogeneities of the 569 pathogen, population makeup, vaccines, and vaccination strategies likely change chronically, 570 which may have important impacts on the trajectory of peak dates, peak sizes, and trade-offs 571 (20,35-38). The results can asymptotically provide an estimate of the traits of the pathogen, traits 572 of the transmission, vaccines paired with social effort for stratified metrics of disease burdens, 573

574 which can be used as long-term evidence-based guidance to the retrospective threshold appraisal 575 of vaccination strategies, social gains/costs and the stratified trade-off analysis in the long term.

- 576
- 577
- 578

#### 579 **References**

- 580 1. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int (2023).
- World Health Organization. WHO COVID-19 vaccines. <u>https://www.who.int/emergencies/diseases/novel-</u> coronavirus-2019/covid-19-vaccines (2023).
- 3. World Health Organization. WHO COVID-19 vaccines. <u>https://www.who.int/publications/m/item/draft-</u>
   landscape-of-covid-19-candidate-vaccines (2023).
- 4. World Health Organization. Interim statement on booster doses for COVID-19 vaccination. https://www.who.int/news/item/22-12-2021-interim-statement-on-booster-doses-for-covid-19-vaccination---update-22-december-2021 (2022).
- B.A. Filardi, V.S. Monteiro, P.V. Schwartzmann, V.P. Martins, L.E.R. Zucca, G.C. Baiocchi, A.A. Malik, J.
   Silva, A.M. Hahn, N.F. G. Chen, K. Pham, E. Perez-Then, M. Miric, V. Brache, L. Cochon, R.A. Larocca,
   R.D.R. Mendez, D. B. Silveira, A.R. Pinto, J. Croda, I. Yildirim, S.B. Omer, A.I. Ko, S.H. Vermund, N.D.
   Grubaugh, A. Iwasaki, C. Lucas, Yale SARS-COV-2 Genomic Surveillance Initiative. Age-dependent
   impairment in antibody responses elicited by a homologous CoronaVac booster dose. Sci. Transl. Med. 15,
   683(2023).
- 6. O.J. Wouters, K.C. Shadlen, M. Salcher-Konrad, A.J. Pollard, H.J. Larson, Y. Teerawattananon, M. Jit.
   Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and
   deployment. Lancet 397,1023–34(2021).
- N.M. Ferguson, D. Laydon, G. Nedjati-Gilani, N. Imai, K. Ainslie, M. Baguelin, S. Bhatia, A. Boonyasiri, Cucunubá, G. Cuomo-Dannenburg, A. Dighe, I. Dorigatti, H. Fu, K. Gaythorpe, W. Green, A. Hamlet, W. Hinsley, L.C. Okell, S.V. Elsland, H. Thompson, R. Verity, E. Volz, H. Wang, Y. Wang, P. G.T. Walker, C.
   Walters, P. Winskill, C. Whittaker, C.A. Donnelly, S. Riley, A.C. Ghani. Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand. DOI: 10.25561/77482.
- 8. X.Y. Ren, J. Zhou, J. Guo, C.M. Hao, M.X. Zheng, R. Zhang, Q. Huang, X.M. Yao, R.L. Li, Y.H. Jin.
  Reinfection in patients with COVID-19: a systematic review. Glob. Health Res. Policy, 7:12(2022).
- 9. J.Y. Chung, M.N. Thone, Y.J. Kwon. COVID-19 vaccines: The status and perspectives in delivery points of view. Adv. Drug. Deliv. Rev. 170, 1–25 (2021).
- S.A. Meo, I.A. Bukhari, J. Akram, A.S. Meo, D.C. Klonoff. COVID-19 vaccines: comparison of
   biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
   Eur. Rev. Med. Pharmacol. Sci. 25, 1663-1669 (2021).
- 11. Mathieu, E. et al. A global database of COVID-19 vaccinations. Nat. Hum. Behav. 5,947-953 (2021).
- 61012. Our World in Data. Statistics and Research Coronavirus (COVID-19)Vaccinations.611https://ourworldindata.org/covid-vaccinations (Accessed on January 5, 2022).Vaccinations.
- 612 13. E.A. Harrison, J.W. Wu. Vaccine confidence in the time of COVID-19. Eur. J. Epidemiol. 35, 325-330 (2020).
- 614 14. N.S. Jecker, Z. Lederman. Three for me and none for you? An ethical argument for delaying COVID-19
  615 boosters. J. Med. Ethics. ,10.1136/medethics-2021-107824 (2021).
- b. M. Skowronski, G.D. Serres. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl.
  J. Med. 384, 1576-1577 (2021).
- E. Vasileiou, C.R. Simpson, T. Shi, S. Kerr, U. Agrawal, A. Akbari, S. Bedston, J. Beggs, D. Bradley, A.
  Chuter, S. de Lusignan, A.B. Docherty, D. Ford, F.R. Hobbs, M. Joy, S.V. Katikireddi, J. Marple, C.
  McCowan, D. McGagh, J. McMenamin, E. Moore, J.L. Murray, J. Pan, L. Ritchie, S.A. Shah, S. Stock, F.
  Torabi, R.S. Tsang, R. Wood, M. Woolhouse, C. Robertson, A. Sheikh. Interim findings from first-dose
  mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national
  prospective cohort study. Lancet 397, 1646–57(2021).
- 624 17. Y.N. Lamb. BNT162b2 mRNA COVID-19 Vaccine: First Approval. Drugs 81(4), 495–501 (2021).
- I8. J. Sadoff, G. Gray, A. Vandebosch, V. Cárdenas, G. Shukarev, B. Grinsztejn, P.A. Goepfert, C. Truyers, H.
  Fennema, B. Spiessens, K. Offergeld, G. Scheper, K.L. Taylor, M.L. Robb, J. Treanor, D.H. Barouch, J.
  Stoddard, M.F. Ryser, M.A. Marovich, K.M. Neuzil, L. Corey, N. Cauwenberghs, T. Tanner, K. Hardt, J.
  Ruiz-Guiñazú, M. L. Gars, H. Schuitemaker, J.V. Hoof, F. Struyf, M. Douoguih, ENSEMBLE Study
  Group. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N. Engl. J. Med.

630 384,2187-201 (2021).

- 19. D.V. Mehrotra, H.E. Janes, T.R. Fleming, P.W. Annunziato, K.M. Neuzil, L.N. Carpp, D. Benkeser, E.R.
  Brown, M. Carone, I. Cho, D. Donnell, M.P. Fay, Y. Fong, S. Han, I. Hirsch, Y. Huang, Y. Huang, O.
  Hyrien, M. Juraska, A. Luedtke, M. Nason, A. Vandebosch, H. Zhou, M.S. Cohen, L. Corey, J. Hartzel,
  D. Follmann, P.B. Gilbert Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trial. Ann.
  Intern. Med. 174(2):221-228 (2021).
- C.M. Saad-Roy, S.E. Morris, C. J. E. Metcalf, M.J. Mina, R.E. Baker, J. Farrar, E.C. Holmes, O.G. Pybus,
  A.L. Graham, S.A. Levin, B.T. Grenfell, C.E. Wagner. Epidemiological and evolutionary considerations of
  SARS-CoV-2 vaccine dosing regimes. Science 372, 363-370 (2021).
- 639 21. B. Experton, H.A. Tetteh, N. Lurie, P. Walker, A. Elena, C.S. Hein, B. Schwendiman, J.L. Vincent, C.R.
  640 Burrow. Model-informed COVID-19 vaccine prioritization strategies by age and serostatus. Science 371,
  641 916–921 (2021).
- 642 22. L. Corey, J.R. Mascola, A.S. Fauci, F.S. Collins. A strategic approach to COVID-19 vaccine R&D.
  643 Science 368, 948-950 (2020).
- 644 23. S. Mallapaty. Researchers fear growing COVID vaccine hesitancy in developing nations. Nature,
   645 10.1038/d41586-021-03830-7(2021).
- P.R. Krause, T.R. Fleming, R. Peto, I.M. Longini, J.P. Figueroa, J.A.C. Sterne, A. Cravioto, H. Rees, J.P.T.
  Higgins, I. Boutron, H. Pan, M.F. Gruber, N. Arora, F. Kazi, R. Gaspar, S. Swaminathan, M.J. Ryan, A.M.
  Henao-Restrepo. Considerations in boosting COVID-19 vaccine immune responses. Lancet 398, 1377–80 (2021).
- 650 25. M. Voysey, S.A.C. Clemens, S.A. Madhi, L.Y. Weckx, P.M. Folegatti, P.K. Aley, B. Angus, V.L. Baillie, S.L. Barnabas, O.E. Bhorat, S. Bibi, C. Briner, P. Cicconi, A.M. Collins, R. Colin-Jones, C.L. Cutland, 651 T.C. Darton, K. Dheda, C.J.A. Duncan, K.R.W. Emary, K.J. Ewer, L. Fairlie, S.N. Faust, S. Feng, D.M. 652 653 Ferreira, A. Finn, A.L. Goodman, C.M. Green, C.A. Green, P.T. Heath, C. Hill, H. Hill, I. Hirsch, S.H.C. 654 Hodgson, A. Izu, S. Jackson, D. Jenkin, C.C.D. Joe, S. Kerridge, A. Koen, G. Kwatra, R. Lazarus, A.M. Lawrie, A. Lelliott, V. Libri, P.J. Lillie, R. Mallory, A.V.A. Mendes, E.P. Milan, A.M. Minassian, A. 655 656 McGregor, H. Morrison, Y.F. Mujadidi, A. Nana, P.J. O'Reilly, S.D. Padayachee, A. Pittella, E. Plested, 657 K.M. Pollock, M.N. Ramasamy, S. Rhead, A.V. Schwarzbold, N. Singh, A. Smith, R. Song, M.D. Snape, E. Sprinz, R.K. Sutherland, R. Tarrant, E.C. Thomson, M.E. Török, M. Toshner, D.P.J. Turner, J. 658 659 Vekemans, T.L. Villafana, M.E.E. Watson, C.J. Williams, A.D. Douglas, A.V.S. Hill, T. Lambe, S.C. Gilbert, A.J. Pollard, Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 660 661 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in 662 Brazil, South Africa, and the UK. Lancet 397,99-111 (2021).
- S.A. Halperin. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of
  recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an
  international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial. Lancet 399, 237248 (2021).
- 667 27. G. Troiano. Vaccine hesitancy in the era of COVID-19. Public Health 194, 245-251 (2021).
- 8. R. Verbeke, I. Lentacker, S.C. De Smedt, H. Dewitte. The dawn of mRNA vaccines: The COVID-19 case.
  J. Control Release. 333, 511–520 (2021).
- S. Yang, Y. Li, L. Dai, J. Wang, P. He, C. Li, X. Fang, C. Wang, X. Zhao, E. Huang, C. Wu, Z. Zhong, F.
  Wang, X. Duan, S. Tian, L. Wu, Y. Liu, Y. Luo, Z. Chen, F. Li, J. Li, X. Yu, H. Ren, L. Liu, S. Meng, J. Yan,
  Z. Hu, L. Gao, G.F. Gao. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based
  protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebocontrolled, phase 1 and 2 trials. Lancet Infect. Dis. 21, 1107–19 (2021).
- 30. N.A. Charania, S.M. Moghadas. Modelling the effects of booster dose vaccination schedules and
  recommendations for public health immunization programs: the case of Haemophilus influenzae serotype
  b. BMC Public Health 17, 705 (2017).
- 578 31. Experton, B. et al. A Predictive Model for Severe COVID-19 in the Medicare Population: A Tool for
   579 Prioritizing Primary and Booster COVID-19 Vaccination. Biology 10, 1185 (2021).
- Katikireddi, S.V. et al. Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital
  admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil.
  Lancet, 10.1016/S0140-6736(21)02754-9 (2021).
- 33. N. Barda, N. Dagan, C. Cohen, M.A. Hernán, M. Lipsitch, I.S. Kohane, B.Y. Reis, R.D. Balicer.
  Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes
  in Israel: an observational study. Lancet 2021, 398, 10316, 2093-2100 (2021).
- Analysis of cases averted for stratified disease burdens during a COVID-19-like pandemic interactive dashboard. https://ichironakamoto.shinyapps.io/analysis\_aversion\_COVID-19-like\_pandemic.

- A. Koirala, Y.J. Joo, A. Khatami, C. Chiu, P.N. Britton. Vaccines for COVID-19: The current state of play.
  Paediatr. Respir. Rev. 35, 43-49 (2020).
- 36. X. Wang, Z. Du, K.E. Johnson, R.F. Pasco, S.J. Fox, M. Lachmann, J.S. McLellan, L.A. Meyers. Effects
   of COVID-19 Vaccination Timing and Risk Prioritization on Mortality Rates, United States. Emerg. Infect.
   Dis. 27(7), 1976-1979 (2021).
- 693 37. O. Milman, I. Yelin, N. Aharony, R. Katz, E. Herzel, A. Ben-Tov, J. Kuint, S. Gazit, G. Chodick, T. Patalon,
  694 R. Kishony. Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals.
  695 Nat. Med. 27, 1367–1369 (2021).
- 88. R.M. Kaplan, A. Milstein. Influence of a COVID-19 vaccine's effectiveness and safety profile on vaccination acceptance. PNAS 118,10, e2021726118 (2021).
- B.F. Haynes, L. Corey, P. Fernandes, P.B. Gilbert, P.J. Hotez, S. Rao, M.R. Santos, H. Schuitemaker, M.
  Watson, A. Arvin. Prospects for a safe COVID-19 vaccine. Sci. Transl. Med. 12, eabe0948 (2020).
- 40. A.A. Dror, N. Eisenbach, S. Taiber, N.G. Morozov, M. Mizrachi, A. Zigron, S. Srouji, E. Sela. Vaccine hesitancy: the next challenge in the fight against COVID-19. Eur. J. Epidemiol. 35,775–779 (2020).
- 41. S. Kashte, A. Gulbake, S.F. El-Amin, A. Gupta. COVID-19 vaccines: rapid development, implications,
   challenges, and future prospects. Hum. Cell 34, 711–733 (2021).
- J. Wu, Q. Li, C.S. Tarimo, M. Wang, J. Gu, W. Wei, M. Ma, L. Zhao, Z. Mu, Y. Miao. COVID-19 Vaccine
   Hesitancy Among Chinese Population: A Large-Scale National Study. Front. Immunol. 12, 781161(2021).
- 43. S. Cele, L. Jackson, D.S. Khoury, K. Khan, T. Moyo-Gwete, H. Tegally, J.E. San, D. Cromer, C.
  Scheepers, D.G. Amoako, F. Karim, M. Bernstein, G. Lustig, D. Archary, M. Smith, Y. Ganga, Z. Jule, K.
  Reedoy, S.H. Hwa, J. Giandhari, J.M. Blackburn, B.I. Gosnell, K.S.S. Abdool, W. Hanekom, NGS-SA,
  COMMIT-KZN Team, A. Gottberg, J.N. Bhiman, R.J. Lessells, M.S. Moosa, M.P. Davenport, T. Oliveira,
  P.L. Moore, A. Sigal. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization.
  Nature 602,654-656 (2021).
- 44. A. M. Ali1, K. M. Ali, M. H. Fatah, H. M. Tawfeeq, H. M. Rostam, SARS-CoV-2 reinfection in patients negative for immunoglobulin G following recovery from COVID-19. New Microbes New Infect. 43, 100926 (2021).
- 45. D. Planas, N. Saunders, P. Maes, F. Guivel-Benhassine, C. Planchais, J. Buchrieser, W.H. Bolland, F.
  Porrot, I. Staropoli, F. Lemoine, H. Péré, D. Veyer, J. Puech, J. Rodary, G. Baele, S. Dellicour, J.
  Raymenants, S. Gorissen, C. Geenen, B. Vanmechelen, T. Wawina-Bokalanga, J. Martí-Carreras, L.
  Cuypers, A. Sève, L. Hocqueloux, T. Prazuck, F.A. Rey, E. Simon-Loriere, T. Bruel, H. Mouquet, E. André,
  O. Schwartz. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature 602, 671675 (2021).
- 46. H. Greter, S. Ivol, V.O. Mathieu, S. Erismann, H. Prytherch, P. Steinmann. Heterologous vaccine regimen:
  Stakeholder acceptance and implementation considerations. Vaccine 39, 580–587 (2021).
- 47. A. Shet, K. Carr, M.C. Danovaro-Holliday, S.V. Sodha, C. Prosperi, J. Wunderlich, C. Wonodi, H.W.
  Reynolds, I. Mirza, M. Gacic-Dobo, K.L. O'Brien, A. Lindstrand.Impact of the SARS-CoV-2 pandemic on routine immunisation services: evidence of disruption and recovery from 170 countries and territories. Lancet Glob. Health. 2022 10, 2, e186-e194.
- 48. C.J. Worby, H.H Chang. Face mask use in the general population and optimal resource allocation during
   the COVID-19 pandemic. Nat. Commun. 11, 4049 (2020).
- 49. K. Li, B. Huang, M. Wu, A. Zhong, L. Li, Y. Cai, Z. Wang, L. Wu, M. Zhu, J. Li, Z. Wang, W. Wu, W. Li,
  B. Bosco, Z. Gan, Q. Qiao, J. Wu, Q. Wang, S. Wang, X. Xia. Dynamic changes in anti-SARS-CoV-2
  antibodies during SARS-CoV-2 infection and recovery from COVID-19. Nat. Commun. 11, 6044 (2020).
- J.H. Kim, F. Marks, J.D. Clemens. Looking beyond COVID-19 vaccine phase 3 trials.Nat. Med. 27, 205–211 (2021).
- 734 51. R. Arbel, A. Hammerman, R. Sergienko, M. Friger, A. Peretz, D. Netzer, S. Yaron. BNT162b2 Vaccine
  735 Booster and Mortality Due to Covid-19. N. Engl. J. Med. 385, 2413-20(2021).
- 52. O.P. Misra, D.K. Mishra. Modelling the effect of booster vaccination on the transmission dynamics of diseases that spread by droplet infection. Nonlinear Anal. Hybrid Syst. 3, 657–665 (2009).
- 738 53. A.P.S. Munro, L. Janani, V. Cornelius, P.K. Aley, G. Babbage, D. Baxter, M. Bula, K. Cathie, K. Chatterjee, 739 K. Dodd, Y. Enever, K. Gokani, A.L. Goodman, C.A. Green, L. Harndahl, J. Haughney, A. Hicks, A.A. 740 Klaauw, J. Kwok, T. Lambe, V. Libri, M.J. Llewelyn, A.C. McGregor, A.M. Minassian, P. Moore, M. Mughal, Y.F. Mujadidi, J. Murira, O. Osanlou, R. Osanlou, D.R. Owens, M. Pacurar, A. Palfreeman, D. 741 742 Pan, T. Rampling, K. Regan, S. Saich, J. Salkeld, D. Saralaya, S. Sharma, R. Sheridan, A. Sturdy, E.C. 743 Thomson, S. Todd, C. Twelves, R.C. Read, S. Charlton, B. Hallis, M. Ramsay, N. Andrews, J.S. Nguyen-Van-Tam, M.D. Snape, X. Liu, S.N. Faust, COV-BOOST study group. Safety and immunogenicity of 744 seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or 745

- BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet
   398, 2258–76 (2021).
- 54. P.R. Krause, T.R. Fleming, R. Peto, I.M. Longini, J.P. Figueroa, J.A.C. Sterne, A. Cravioto, H. Rees, J.P.T.
  Higgins, I. Boutron, H. Pan, M.F. Gruber, N. Arora, F. Kazi, R. Gaspar, S. Swaminathan, M.J. Ryan, A.M.
  Henao-Restrepo. Considerations in boosting COVID-19 vaccine immune responses. Lancet 398, 10308, 1377-1380 (2021).
- 55. E.J. Haas, J.M. McLaughlin, F. Khan, F.J. Angulo, E. Anis, M. Lipsitch, S.R. Singer, G. Mircus, N. Brooks,
  M. Smaja, K. Pan, J. Southern, D.L. Swerdlow, L. Jodar, Y. Levy, S. Alroy-Preis.Infections,
  hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer–BioNTech
  BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study. Lancet Infect Dis 22,
  357–66 (2022).

797

# 798 Acknowledgments

I.N. acknowledges W. Chen for helpful discussions regarding the calibration analysis ofparameters.

801

#### 802 803 **Funding:**

- 804 The study was partially supported by the following funding.
- 805 Undergraduate Teaching Reform Foundation of Fujian University and Technology grant 806 2022JG041
- Graduate Teaching Reform and Textbook Publication Foundation of Fujian University and
   Technology grant YJC22-1
- 809 China Ministry of Education Industry and Education Cooperation Project grant 202002041005
- 810 National Social Science Foundation of China grant 22BGL007
- 811 Natural Science Funding of Fujian Province grant 2020J01892
- 812 Fujian Zhi-lian-yun Supply Chain Technology and Economy Integration Service Platform,
- Fujian-Kenya Silk Road Cloud Joint R&D Center grant 2021D021
- Fujian Provincial Department of Science and Technology, the Fujian Social Sciences Federation
   Planning Project grant FJ2021Z006
- 816 General program of Fujian Natural Science Foundation grant 2022J01941
- 817 Fujian Provincial Department of Education Project grant JAT220230
- 818 Research Project of Major Education and Teaching Reform in Fujian Universities grant 819 FBJG20190174
- 820 Initial Scientific Research Fund in Fujian University of Technology grant GY-Z220292
- Fujian Provincial Department of Education Project grant JAT220230
- 822 823

## 824 Author contributions:

I.N. conceived the study, developed the model, wrote the coding and performed analysis, and
 produced and revised the manuscript. All authors contributed to the final draft.

## 828 **Competing interests:**

- 829 The author declares no competing interests.
- 830

827

# 831832 Data and materials availability:

833 All data needed to estimate the conclusions in the study are present in the paper, the Supplementary Materials, and/or the Supplementary Data. The code used in the analysis is 834 available at https://github.com/wcg305/prevention cyclical resurgence COVID-19. The 835 836 interactive dashboard addressing the sensitivity tests and key parameters discussed in the manuscripts is accessible from address 837 the https://ichironakamoto.shinyapps.io/analysis aversion COVID-19-like pandemic. Additional 838 839 data related to this paper may be requested from the corresponding author.

840 841

## 842 Supplementary Materials

- Please refer to the supplementary material for detailed information regarding the mathematical model, the parameters used in the simulations, and the results of the sensitivity tests.
- 845